suggested remit: To appraise the clinical and cost effectiveness of burosumab within its marketing authorisation for treating X-linked hypophosphatemia (XLH) in adults
Status Proposed
Process STA 2018
ID number 3822

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
04 March 2021 (10:00) Scoping workshop
07 January 2021 - 04 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance